Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
aLoOxMBMC
- Development stage
- Unknown
- Lead developer
- ALTACO-XXI
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
aLoOxMBMC is an investigational allogeneic cell therapy product consisting of ischemia-tolerant mesenchymal stem cells (MSCs) derived from human bone marrow. Developed by Altaco XXI, LLP, these cells are cultured under low-oxygen (hypoxic) conditions to enhance their survival and therapeutic potential within the ischemic environment of the heart. The therapy is administered as a single intravenous dose to patients following an acute myocardial infarction (AMI), including both ST-elevation (STEMI) and non-ST-elevation (NSTEMI) cases. The mechanism of action involves the cells' ability to secrete paracrine factors that stimulate angiogenesis, modulate the inflammatory response, and potentially facilitate the repair of damaged cardiac tissue, thereby improving cardiac function and preventing adverse ventricular remodeling.
- Other names
- allogeneic ischemia tolerant mesenchymal bone marrow cellshuman allogeneic ischemia tolerant mesenchymal bone marrow cellsallogeneic low oxygen mesenchymal stem cells
Beyond the preview
Go deeper on aLoOxMBMC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on aLoOxMBMC.